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StratificationAbstract Background: The benefit of second-line chemotherapy (L2) over standard first-line
(L1) gemcitabine plus cisplatin (GEMCIS) or oxaliplatin (GEMOX) chemotherapy in
advanced biliary tract cancer (aBTC) is unclear. Our aim was to identify and validate prog-
nostic factors for overall survival (OS) with L2 in aBTC to guide clinical decisions in this
setting.
Methods: We performed a retrospective analysis of four prospective patient cohorts: a develop-
ment cohort (28 French centres) and three validation cohorts from Italy, UK and France. All
consecutive patients with aBTC receiving L2 after GEMCIS/GEMOX L1 between 2003 and
2016were included. The association of clinicobiological datawithOSwas investigated in univar-
iate and multivariate Cox analyses. A simple score was derived from the multivariate model.
Results: The development cohort included 405 patients treated with L1 GEMOX (91%) or
GEMCIS. Of them, 55.3% were men, and median age was 64.8 years. Prior surgical resection
was observed in 26.7%, and 94.8% had metastatic disease. Performance status (PS) was 0, 1
and 2 in 17.8%, 52.4% and 29.7%, respectively. Among 22 clinical parameters, eight were asso-
ciated withOS in univariate analysis. Inmultivariate analysis, four were independent prognostic
factors (p< 0.05): PS, reason forL1 discontinuation, prior resection of primary tumour andperi-
toneal carcinomatosis. The model had the Harrell’s concordance index of 0.655, a good calibra-
tion and was validated in the three external cohorts (NZ 392).
Conclusion: We validated previously reported predictive factors of OS with L2 and identified
peritoneal carcinomatosis as a new pejorative factor in nearly 800 patients. Ourmodel and score
may be useful in daily practice and for future clinical trial design.
ª 2019 Elsevier Ltd. All rights reserved.1. Introduction
Although of low incidence (w12,000 new cases/year in
Europe), biliary tract cancers (BTCs) are the second pri-
mary liver tumour after hepatocellular carcinoma [1].
They are classified into three subtypes based on anatomic
location: (1) intrahepatic cholangiocarcinoma (CCA); (2)
extrahepatic CCA and (3) gallbladder carcinoma [2,3].
Their prognosis is poor, mainly because of late diagnosis,
frequently at an advanced stage (w65%) [2,3]. The 5-year
overall survival (OS) rate is only 18% [4].Therapeutic options for advanced BTC (aBTC) are
limited [2,3]. In 2010, the gemcitabine plus cisplatin
(GEMCIS) doublet became the first-line (L1) reference
chemotherapy based on the ABC-02 phase III trial,
which showed the superiority of GEMCIS over gemci-
tabine in patients with aBTC and Eastern Cooperative
Oncology Group (ECOG) performance status (PS)  2
[5]. Similar results were found in a Japanese randomised
phase II trial [6] and in a meta-analysis pooling the re-
sults from these two studies [7]. Owing to better toler-
ance and simpler outpatient administration, many
C. Neuzillet et al. / European Journal of Cancer 111 (2019) 94e10696European centres use the GEMOX (gemcitabine plus
oxaliplatin) doublet as an equivalent to GEMCIS [8].
Overall, gemcitabine plus platinum chemotherapy is
well-established L1 standard in patients with aBTC and
a PS  2 [2,3].
Beyond failure of L1, up to 30%e40% of patients
remain in a good clinical condition and are able to receive
subsequent line(s) of therapy [10]. There is no recom-
mended treatment in this setting [2,3]. In a systematic
review of the literature, Lamarca et al. [11] reported a
median OS of 7.2 months with second-line chemotherapy
(L2) in patients with aBTC. The ABC-07 phase III trial
(NCT01926236) is ongoing to assess the clinical benefit of
L2 administration vs. best supportive care (BSC).
Not all patients seem to benefit from L2, and it has to
be discussed in terms of risk/benefit ratio on an indi-
vidual basis. Thus, identification of reliable prognostic
factors for risk stratification of patients with aBTC in
L2 setting is warranted to improve therapeutic decisions.
However, there is no well-validated and widely accepted
prognostic model for application in routine practice or
in clinical trials.
We performed a multicenter European study to
develop and validate a prognostic model and score for
OS in patients with aBTC treated with L2. The model
and score may be useful tools to guide clinicians’ deci-
sion for L2 administration and to optimise future clin-
ical trial design.2. Materials and methods
2.1. Patients
All consecutive patients with histologically proven
aBTC who were treated between January 2003 and
January 2016 in 28 French centres were included in the
development cohort. Patients were considered eligible if
they (i) were 18 years old, (ii) had aBTC (metastatic,
locally advanced or recurrent after surgery) not
amenable to curative treatment and (iii) had progressed
or were intolerant to L1 with gemcitabine plus platinum
(GEMCIS or GEMOX). Patients were excluded if they
(i) had been treated with gemcitabine plus platinum
doublet in the adjuvant setting, (ii) received L1 gemci-
tabine single agent or (iii) had an ampullary carcinoma.
The external validation cohorts included consecutive
patients with aBTC who received L2 between January
2003 and January 2016 with the same inclusion criteria
in three other cohorts: (i) an Italian multicenter cohort
(nine centres), (ii) a United Kingdom (UK) single-
institutional cohort (Barts Cancer Institute,
London) and (iii) a French single-institutional cohort
(Gustave Roussy Institute, Villejuif).
The database was registered and declared to the
National French Commission for bioinformatics data
and patient liberty and approved by the AdvisoryCommittee on Information Processing in the field of
health research (declaration number: 14e115). In
accordance with French regulation, an information let-
ter was given to all patients and non-opposition was
verified.
Demographics; cancer history and treatment and
pathological, clinical, biological and radiological
(tumour response as per Response Evaluation Criteria
in Solid Tumours, v1.1, criteria) data were retrospec-
tively collected from medical records.
2.2. Statistical analysis
Median value (interquartile range) and frequency (per-
centage) were provided for the description of continuous
and categorical variables, respectively. Medians and
proportions were compared using Student’s t-test and
chi-squared test (or Fisher’s exact test, if appropriate),
respectively.
OS with L2 was calculated from the date of first
administration of L2 to the date of death from any
cause. Survival data were censored at the last follow-up.
OS with L2 was estimated using the KaplaneMeier
method and described using median or rate at specific
time points with 95% confidence intervals (95% CIs).
Follow-up duration was calculated using a reverse
KaplaneMeier estimation [12].
Cox proportional hazard models were performed to
estimate hazard ratio (HR) and 95% CI for factors
associated with OS in L2. The association of 22 baseline
parameters with OS in L2 was first assessed using uni-
variate Cox analyses, and then parameters with p
values < 0.05 were entered into a final multivariable Cox
regression model, after considering collinearity among
variables with a correlation matrix. When used contin-
uously in the Cox model, a potential non-linear rela-
tionship between predictors and OS was first
investigated using the fractional polynomials method to
determine the best transformation for continuous vari-
ables [13] and validated by the restricted cubic splines
method with graphical evaluation. The assumption of
proportionality was checked by plotting log-minus-log
survival curves and by cumulative martingale process
plots.
Accuracy of the final model was verified regarding
two parameters: discrimination and calibration. The
predictive value and the discrimination ability of the
final model were assessed with the Harrell’s concordance
index (C-index) [14]. Random samples of the population
were used to derive 95% CI bootstrap percentile for the
C-statistic. Calibration was assessed by visual exami-
nation of the calibration plot. Internal validation of the
final model was performed with a bootstrap sample
procedure.
The final model was used to establish a nomogram,
allowing the estimation of median and individual L2 OS
probabilities at 3, 6, 12 and 24 months. At a population
Table 1
Patient characteristics in the development and external validation cohorts.
Characteristics Development cohort External validation cohorts
AGEO CT2BIL (n Z 405) Italy (n Z 297) France (n Z 71) UK (n Z 24)
Sexa
Male 224 (55.3%) 150 (50.5%) 34 (47.9%) 12 (50.0%)
Age (years), median (IQR) 64.8 (58.2e71.3) 64.7 (57.2e69.9) 62.6 (56.3e68.9) 66.7 (59.7e72.5)
Missing 0 1 1 0
Primary tumour site
Intrahepatic 214 (53.1%) 171 (57.6%) 43 (60.6%) 10 (41.7%)
Extrahepatic/hilar 109 (27.1%) 72 (24.2%) 14 (19.7%) 4 (16.6%)
Gallbladder 80 (19.8%) 54 (18.2%) 14 (19.7%) 10 (41.7%)
Missing 2 0 0 0
Prior resection of primary tumoura,b
Yes 108 (26.7%) 92 (31.0%) 9 (12.7%) 7 (29.2%)
Radiotherapy
Yes 25 (6.2%) 23 (7.7%) 5 (7.0%) 3 (13.0%)
Missing 3 0 0 1
Biliary drainage
Yes 129 (32.3%) 65 (22.1%) 22 (31.0%) 7 (30.4%)
Missing 6 3 0 1
Type of L1 regimen
Gemcitabine þ oxaliplatin 368 (90.9%) 176 (59.3%) 66 (94.3%) 0 (0%)
Gemcitabine þ cisplatin 37 (9.1%) 121 (40.7%) 4 (5.7%) 24 (100.0%)
Missing 0 0 1 0
Best response to L1
CR 14 (3.5%) 3 (1.0%) 2 (2.9%) 0 (0%)
PR/SD 251 (62.8%) 178 (59.9%) 49 (70.0%) 19 (79.2%)
PD 135 (33.8%) 116 (39.1%) 19 (27.1%) 5 (20.8%)
Missing 5 0 1 0
Duration of L1 (months)c 6.4 (3.2e11.0) 6.5 (3.7e9.7) 5.9 (2.9e9.4) 11.0 (7.2e18.3)
Missing 0 2 0 0
Reason for L1 discontinuation
Toxicity 42 (10.4%) 25 (8.5%) 7 (9.9%) 2 (8.3%)
Other 51 (12.6%) 76 (25.9%) 7 (9.9%) 13 (54.2%)
PD 312 (77.0%) 193 (65.7%) 57 (80.3%) 9 (37.5%)
Missing 0 3 0 0
PS at the beginning of L2
0 69 (17.8%) 88 (30.4%) 24 (33.8%) 7 (29.2%)
1 203 (52.4%) 152 (52.6%) 32 (45.1%) 10 (41.7%)
2 115 (29.7%) 49 (17.0%) 15 (21.1%) 7 (29.1%)
Missing 18 8 0 2
Disease stage at the beginning of L2
Metastatic 384 (94.8%) 281 (94.9%) 68 (95.8%) 24 (100.0%)
Locally advanced 21 (5.2%) 15 (5.1%) 3 (4.2%) 0 (0%)
Missing 0 1 0 0
Metastatic sites
Livera (yes) 251 (62.0%) 185 (62.3%) 47 (66.2%) 15 (62.5%)
Lung (yes) 116 (28.6%) 79 (26.9%) 20 (28.2%) 4 (16.7%)
Missing 0 3 0 0
Bone (yes) 39 (9.6%) 32 (10.9%) 9 (12.7%) 4 (16.7%)
Missing 0 4 0 0
Lymph node (yes) 139 (34.3%) 156 (53.1%) 39 (54.9%) 13 (54.2%)
Missing 0 3 3 0
Peritoneum (yes) 151 (37.3%) 81 (27.5%) 24 (33.8%) 6 (25.0%)
Missing 0 3 0 0
Total bilirubin (mmol/L), median (IQR) 12.0 (7.0e17.0) 10.3 (7.2e15.4) 9.0 (7.0e19.0) 7.5 (5.5e9.5)
Missing 109 58 28 0
Albumin (g/L), median (IQR) 34.5 (30.0e38.5) 36.0 (31.0e39.0) 34.5 (29.0e39.0) 40.0 (36.0e42.5)
Missing 238 123 37 0
Serum CA19-9 (UI/mL), median (IQR) 166.0 (38.0e1139.0) 161.0 (40.1e1099.0) 470.0 (73.0e5212.0) 335.0 (62.0e847.0)
Missing 154 60 28 10
Type of L2 regimen
Fluoropyrimidine monotherapy 63 (15.6%) 98 (33.0%) 12 (17.4%) 15 (62.5%)
Fluoropyrimidine þ irinotecan 194 (47.9%) 60 (20.2%) 16 (23.2%) 0 (0.0%)
Fluoropyrimidine þ platinum 94 (23.2%) 16 (5.4%) 4 (5.8%) 7 (29.2%)
(continued on next page)
C. Neuzillet et al. / European Journal of Cancer 111 (2019) 94e106 97
Table 1 (continued )
Characteristics Development cohort External validation cohorts
AGEO CT2BIL (n Z 405) Italy (n Z 297) France (n Z 71) UK (n Z 24)
Gemcitabine-based combination 28 (6.9%) 91 (30.6%) 15 (21.7%) 2 (8.3%)
Taxane 5 (1.2%) 5 (1.7%) 2 (2.9%) 0 (0.0%)
Others 21 (5.2%) 27 (9.1%) 20 (29.0%) 0 (0.0%)
CA19-9: carbohydrate antigen 19-9, CR: complete response, IQR: interquartile range, L1: first-line treatment, L2: second-line treatment, PD:
progressive disease, PR: partial response, PS: performance status, SD: stable disease.
a No missing data.
b Prior resection of the primary tumour was defined as surgery with R0/R1 resection and no evidence of disease within 1 month after surgery.
c Duration of L1 was calculated from the date of first administration of L1 to the date of first administration of L2.
C. Neuzillet et al. / European Journal of Cancer 111 (2019) 94e10698level, to define risk groups with distinct survival profiles,
we constructed a simple score based on the prognostic
factors identified and considering their relative weight
on OS. The prognostic score discrimination ability (C-
index) was assessed in each cohort.
A clinical benefitecentred accuracy of the final model
was evaluated by a decision curve analysis [15] in each
cohort.
Another multivariate analysis was performed by
including carbohydrate antigen 19-9 (CA19-9) but not
initially selected in the multivariate model because of the
high rate of missing data.
All analyses were performed using SAS, version 9.4,
and R software, version 2.15.2. P values of less than 0.05
were considered statistically significant, and all tests
were two-sided. More details are provided in the Sup-
plementary Material.
3. Results
3.1. Population-based prospective cohort
The development cohort included 405 patients
treated with L1 GEMOX (91%) or GEMCIS (9%)
[Table 1]. Median follow-up was 34.6 months (95%
CI Z 28.9e51.4).
In the external validation cohorts, 297, 71 and 24
patients were included in the Italian, French and UK
cohort, respectively. The cohorts displayed similar pa-
tient characteristics [Table 1], except for (i) primary
tumour location, (ii) prior surgical resection of the pri-
mary tumour, (iii) L1 regimen and (iv) ECOG PS at the
beginning of L2.
3.2. Determinants of OS in patients receiving second-line
therapy
In univariate Cox analysis, we identified nine parameters
as prognostic factors for OS with p values < 0.05: (i)
prior resection of primary tumour, (ii) biliary drainage,
(iii) best tumour response with L1, (iv) duration of L1,
(v) reason for L1 discontinuation, (vi) ECOG PS at the
beginning of L2, (vii) number of metastatic sites, (viii)
bone metastases and (ix) peritoneal carcinomatosis[Table 2A and Supplementary Figure 1]. Primary
tumour site and type of L2 regimen were not signifi-
cantly associated with OS.
A correlation matrix was used to detect relevant in-
teractions between investigated parameters and select
variables for multivariate analysis [Supplementary
Figure 2].
The multivariable Cox analysis showed four inde-
pendent risk factors for OS: (i) ECOG PS (p < 0.0001),
(ii) reason for L1 discontinuation (p Z 0.0020), (iii)
prior resection of primary tumour (pZ 0.0314), and (iv)
peritoneal carcinomatosis (p Z 0.0181) [Table 2B]. The
type of L2 regimen was not associated with OS
(p Z 0.8129).
3.3. Performance assessment and internal validation of the
final model
The multivariate model had a C-index of 0.655 (95%
CI Z 0.621e0.688). The calibration plots showed an
optimal agreement between model prediction and actual
observation for predicting OS probability at 3, 6, 12 and
24 months [Supplementary Figure 3]. In the internal
validation, uncertainties around HR measured with a
bootstrapping procedure reflected the robustness of the
final model [Table 2B].
3.4. Prognostic nomogram and score for OS
A nomogram integrating all statistically significant in-
dependent factors for OS was built [Supplementary
Figure 4].
The nomogram highlighted that ECOG PS had a
heavily predominant weight on OS [Fig. 1A and
Supplementary Figure 4], whereas the prognostic sig-
nificance of other factors was much lower and of similar
magnitude of association with OS. Nevertheless, the
addition of the three other identified risk factors to the
PS in the model significantly improved its discrimination
capacity because the C-statistics increased from 0.624 to
0.655 (delta: 0.03, 95% CI Z 0.01e0.05).
Therefore, we decided to consider reason for L1
discontinuation, prior primary tumour surgery and
peritoneal carcinomatosis as risk factors of equivalent
Table 2A
Prognostic factors associated with overall survival in univariate analysis in the development cohort.
Parameters Number of patients Number of events HR 95% CI p
Sexa
Female 181 152 1 e e
Male 224 194 1.114 [0.900; 1.378] 0.3214
Age (yearsa)
Continuous 405 346 1.006 [0.994; 1.017] 0.3336
Age (yearsa)
<70 286 240 1 e e
70 119 106 1.073 [0.852; 1.350] 0.5498
Primary tumour site
Intrahepatic 214 190 1 e
Extrahepatic/hilar 109 89 0.965 [0.750; 1.242]
Gallbladder 80 66 1.042 [0.787; 1.379] 0.8950
Missing 2
Prior resection of primary tumoura,b
Yes 108 84 1
No 297 262 1.615 [1.259; 2.073] 0.0002
R0 resection of primary tumour
Yes 73 56 1
No 33 26 1.251 [0.780; 2.007] 0.3535
Missing 2
Radiotherapy
Yes 25 22 1
No 377 321 1.043 [0.676; 1.609] 0.8487
Missing 3
Biliary drainage
Yes 129 108 1
No 270 232 0.735 [0.583; 0.925] 0.0087
Missing 6
Delay between diagnosis of advanced BTC and beginning of L1a
< 1 month 169 144
1e3 months 206 178 1.167 [0.934; 1.457]
> 3 months 30 24 0.787 [0.510; 1.215] 0.1220
Type of L1 regimena
Gemcitabine þ oxaliplatin 368 316 1
Gemcitabine þ cisplatin 37 30 0.843 [0.580; 1.227] 0.3734
Best response to L1
CR 14 10 1
PR/SD 251 219 2.270 [1.199; 4.298]
PD 135 114 2.924 [1.518; 5.631] 0.0022
Missing 5
Duration of L1c (monthsa)
Continuous 405 346 0.980 [0.964; 0.997] 0.0194
Duration of L1c (monthsa)
< 3 82 73 1
3e6 111 89 0.939 [0.689; 1.280]
> 6 212 184 0.747 [0.569; 0.982] 0.0573
Reason for L1 discontinuationa
Toxicity/Other 93 80 1
PD 312 266 1.691 [1.311; 2.182] <0.0001
PS at the beginning of L2
0 69 53 1
1 203 175 1.817 [1.327; 2.489]
2 115 103 3.647 [2.582; 5.152] <0.0001
Missing 18
Disease stage at the beginning of L2a
Metastatic 384 330 1
Locally advanced 21 16 0.758 [0.458; 1.253] 0.2793
Number of metastatic sites at the beginning of L2a
Continuous 405 346 1.158 [1.049; 1.279] 0.0037
Number of metastatic sites at the beginning of L2a
< 2 153 127 1
 2 252 219 1.289 [1.034; 1.606] 0.0238
Liver metastasisa
(continued on next page)
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Table 2A (continued )
Parameters Number of patients Number of events HR 95% CI p
No 154 132 1
Yes 251 214 1.117 [0.899; 1.388] 0.319
Lung metastasis
No 289 242 1
Yes 115 103 1.103 [0.875; 1.392] 0.4069
Missing 1
Bone metastasis
No 365 310 1
Yes 39 35 1.563 [1.099; 2.222] 0.0129
Missing 1
Lymph node metastasis
No 265 229 1
Yes 139 116 1.092 [0.873; 1.366] 0.4396
Missing 1
Peritoneal carcinomatosis
No 254 206 1
Yes 150 139 1.449 [1.167; 1.798] 0.0008
Missing 1
Total bilirubin (mmol/L)
Continuous 296 254 1.010 [1.004; 1.016] <0.0001
Missing 109
Total bilirubin (mmol/L)
17 244 204 1
>17 52 50 1.666 [1.220; 2.275] 0.0013
Missing 109
Albumin (g/L)
Continuous 167 143 0.947 [0.923; 0.971] <0.0001
Missing 238
Albumin (g/L)
<35 g/L 88 84 1
35 g/L 79 59 0.500 [0.355; 0.704] <0.0001
Missing 238
Serum CA 19-9 (UI/mL)
Continuous (log value) 251 207 1.359 [1.188; 1.556] <0.0001
Missing 154
Serum CA 19-9 (UI/mL)
<400 162 130 1
400 89 77 1.878 [1.411; 2.500] <0.0001
Missing 154
Type of L2 regimena
Fluoropyrimidine monotherapy 63 57 1
Fluoropyrimidine þ irinotecan 194 154 0.969 [0.714; 1.314]
Fluoropyrimidine þ platinum 94 88 0.871 [0.624; 1.217]
Gemcitabine-based combination 28 26 0.785 [0.493; 1.249]
Taxane 5 3 0.764 [0.239; 2.443]
Others 21 18 0.787 [0.463; 1.339] 0.8129
Fluoropyrimidine-based regimena
No 50 44 1
Yes 355 302 1.058 [0.771; 1.453] 0.7274
Targeted therapya
No 377 319 1
Anti-EGFR: cetuximab or erlotinib 8 8 0.804 [0.397; 1.629]
Antiangiogenic: bevacizumab or sunitinib
or sorafenib
20 19 0.981 [0.617; 1.560] 0.8316
Center locationa
Paris area 172 137 1
Other French centres 233 209 1.141 [0.919; 1.417] 0.2316
95% CI: 95% confidence interval, EGFR: epidermal growth factor receptor, CA 19-9: carbohydrate antigen 19-9, HR: hazard ratio, L1: first-line
treatment, L2: second-line treatment, PD: progressive disease, PR: partial response, PS: performance status, SD: stable disease, BTC: biliary tract
cancer, CR: complete response.
a No missing data.
b Prior resection of the primary tumour was defined as surgery with R0/R1 resection and no evidence of disease within 1 month post-surgery.
c Duration of L1 was calculated from the date of first administration of L1 to the date of first administration of L2.
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stratum [Supplementary Figure 5]. We observed that the
survival curves of patients with one, two or three risk
factors were quite similar, whereas patients with no risk
factor had a more favourable survival. We then defined
two groups of patients: (i) those with  one risk factor(s)
vs. (ii) those with no risk factor.
The CT2BIL prognostic score was based on the
ECOG PS and the presence of risk factors [Fig. 1BeC].
Finally, owing to the low number of patients with score
0, we grouped scores 0 and 1 together [Supplementary
Figure 6]. Hence, patients were categorised into three
risk groups with median OS of 12.7 months (95%
CI Z 8.5e14.9, score 0e1), 6.9 months (95%
CI Z 6.5e8.5, score 2) and 3.5 months (95%
CI Z 3.0e4.2, score 3), respectively (p < 0.0001)
[Fig. 1BeC]. The C-index of the final score was 0.633,
95% CI Z 0.602e0.663.3.5. External validation of the prognostic model and score
Information for the four baseline parameters that were
required for the score calculation was available for 285
(95.9%), 71 (100%) and 24 (100%) patients from the
Italian, French and UK cohorts, respectively. The
multivariate model was replicated in all three cohorts
[Table 3AeC].
The good discrimination ability of the final model
was externally confirmed with C-index of 0.651 (95%
CIZ 0.615e0.687), 0.704 (95% CIZ 0.590e0.818) andTable 2B
Prognostic factors associated with overall survival in multivariate analysis
Parameters Number
of patients
Number
of events
HR
Prior resection of primary tumoura
Yes 103 79 1
No 284 252 1.333
Reason for discontinuation of L1
Toxicity/
other
92 80 1
PD 295 251 1.506
PS at the beginning of L2
0 69 53 1
1 203 175 1.537
2 115 103 3.045
Peritoneal carcinomatosis
No 241 196 1
Yes 146 135 1.309
Multivariate Cox final model.
95% CI: 95% confidence interval, BCA: accelerated bootstrap, HR: hazard r
disease, PS: performance status.
a Prior resection of the primary tumour was defined as surgery with R0/R0.867 (95% CI Z 0.770e0.964) in the Italian,
French and UK cohorts, respectively.
Then, we validated the discrimination ability of the
score developed by identifying three risk groups with
distinct OS outcomes (p < 0.0001 in each cohort)
[Fig. 2eF].
3.6. Clinical benefit analysis
The clinical benefitecentred accuracy of the final model
was confirmed by a decision curve analysis [Fig. 3AeD].
The net benefit for decisions based on the PS was better
than considering patients on the same level of risk in
each cohort. Our final multivariate model further
improved the benefit for threshold values > 10%.
Overall, the decision curve showed that the net benefit
for decision based on our final multivariable model is of
interest.
3.7. Clinicobiological model
In an exploratory approach, CA19-9 serum level was
added in the previously identified clinical model. Anal-
ysis of CA19-9 as a continuous (log) variable was more
informative than the categorical model (<vs.  400 UI/
mL).
Analysis of patients with complete data for the four
clinical factors and CA19-9 identified CA19-9 as an in-
dependent marker significantly associated with OS
(p Z 0.008 in the development cohort and p < 0.0001in the development cohort (n Z 387).
95% CI p Internal
validation
95% BCA HR
[1.026;
1.733]
0.0314 [0.990; 1.724]
[1.162;
1.952]
0.0020 [1.176; 1.927]
[1.114;
2.121]
[1.180; 2.133]
[2.139;
4.335]
<0.0001 [2.010; 4.577]
[1.047;
1.636]
0.0181 [1.008; 1.688]
atio, L1: first-line treatment, L2: second-line treatment, PD: progressive
1 resection and no evidence of disease within 1 month post-surgery.
Fig. 1. KaplaneMeier curves of the overall survival estimation and
its 95% confidence interval (95% CI) for three risk groups in the
development cohort based on performance status (PS) (p < 0.0001)
(A) or on the CT2BIL score (p < 0.0001) (B), with user-friendly
guide for CT2BIL score calculation (C). Log-rank tests. RF: risk
factor (reason for L1 discontinuation, prior resection of primary
tumour, and peritoneal carcinomatosis).
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horts, respectively) [Supplementary Table 1]. The
multivariate model with CA19-9 was established based
on patients for whom the five parameters were available.
Overall, CA19-9 provided additional prognostic infor-
mation, but the increase in the C-index value was
modest [Supplementary Table 1].4. Discussion and conclusions
Identification of prognostic factors for risk stratification
of patients with aBTC in L2 setting is warranted to
determine which patients are the most likely to benefit
from the administration of chemotherapy. A pre-L2
estimation of OS may be useful to select patients for
treatment, considering that patients who are at high risk
of death within three months should not receive
chemotherapy and should rather be managed with BSC
only. In previously published studies, PS, response to
L1, tumour stage, primary tumour location, prior sur-
gical resection of the primary tumour and CA19-9 were
independently associated with OS with L2 (mainly 5-
fluorouracilebased chemotherapy) [Table 4] [10,16e18].
Our results validate, in nearly 800 patients from four
independent cohorts treated with various types of L2
regimen, some of these previously reported prognostic
factors (ECOG PS, L1 efficacy, primary tumour sur-
gery, CA19-9) and identify peritoneal carcinomatosis as
a new pejorative prognostic factor. This is the largest
database available in aBTC in the L2 setting
[10,16e18]. We performed our analysis in a rigorous
methodological framework [19] and provided trans-
parent reporting of the multivariate model as suggested
in the Transparent Reporting of a multivariable pre-
diction model for Individual Prognosis Or Diagnosis
(TRIPOD) statement [13,20]. These prognostic models
and derived tools could be useful to strengthen
decision-making for clinicians and be applied to the
stratification of patient randomisation and for pre-
planned subgroup analyses in future clinical trials.
However, we acknowledge that our study is limited by
its retrospective nature for data collection and the high
rate of missing data for biological data, requiring
further prospective validation.
Moreover, our work highlights the prognostic
burden of PS in aBTC and provides a word of caution
when making statistical assumptions and interpreting
results from single-arm phase II studies in the L2
setting. Indeed, the majority of trials enrol patients
with PS 0e1 only, who display a clearly more favour-
able survival (median OS up to 13 months in PS 0) than
the overall 6e7 months estimation that has been clas-
sically reported in ‘real life’ studies in the overall (PS
0e2) patient population. Consequently, although it
may be challenging because of the low incidence of this
disease, our results strongly support prospective eval-
uation of OS in BTC in L2 setting and the use of at
least non-comparative randomised phase II design
including a control arm to verify the calibration of the
assumptions made in the experimental arm. This is
even more crucial given the paucity of phase III studies
in these patients.
Finally, the C-index remains <0.70, indicating that
an important part of the patient heterogeneity in death
Table 3A
Prognostic factors associated with overall survival in multivariate analysis in the Italian validation cohort (n Z 285).
Parameters Number of patients Number
of events
HR 95% CI p
Prior resection of primary tumour
Yes 85 71 1
No 201 174 1.454 [1.093; 1.933] 0.0100
Reason for discontinuation of L1
Toxicity/
Other
99 80 1
PD 187 165 1.839 [1.393; 2.427] <0.0001
PS at the beginning of L2
0 88 75 1
1 149 125 1.231 [0.913; 1.658]
2 49 45 2.198 [1.488; 3.247] 0.0003
Peritoneal carcinomatosis
No 206 175 1
Yes 80 70 1.399 [1.049; 1.865] 0.0223
Multivariate Cox final model.
95%CI: 95%confidence interval,HR: hazard ratio,L1: first-line treatment, L2: second-line treatment, PD:progressive disease, PS: performance status.
Table 3B
Prognostic factors associated with overall survival in multivariate analysis in the French validation cohort (n Z 71).
Number
of patients
Number of events HR 95% CI p
Prior resection of primary tumour
Yes 62 48 1
No 9 7 1.851 [0.786; 4.362] 0.1591
Reason for discontinuation of L1
Toxicity/
Other
14 8 1
PD 57 47 3.078 [1.388; 6.823] 0.0063
PS at the beginning of L2
0 24 15
1 32 27 1 [1.015; 3.876]
2 15 13 1.984
6.704
[2.909;
15.452]
<0.0001
Peritoneal carcinomatosis
No 47 35 1
Yes 24 20 1.003 [0.568; 1.769] 0.9928
Multivariate Cox final model.
95%CI: 95%confidence interval,HR: hazard ratio,L1: first-line treatment, L2: second-line treatment, PD:progressive disease, PS: performance status.
Table 3C
Prognostic factors associated with overall survival in multivariate analysis in the UK validation cohort (n Z 24).
Number
of patients
Number
of events
HR 95% CI p
Prior resection of primary tumour
Yes 7 6 1
No 17 15 4.788 [1.032; 22.209] 0.0454
Reason for discontinuation of L1
Toxicity/
Other
15 12 1
PD 9 9 31.893 [5.151; 197.464] 0.0002
PS at the beginning of L2
0 7 5 1
1 10 9 7.441 [1.287; 43.025]
2 7 7 20.421 [2.843; 146.701] 0.0110
Peritoneal carcinomatosis
No 18 15 1
Yes 6 6 15.327 [2.977; 78.900] 0.0011
Multivariate Cox final model.
95%CI: 95%confidence interval,HR: hazard ratio,L1: first-line treatment, L2: second-line treatment, PD:progressive disease, PS: performance status.
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Fig. 2. KaplaneMeier curves of overall survival for three risk groups in the external validation cohorts based on performance status (PS) (A,
p < 0.0001; B, p < 0.0001; C, p < 0.0001) or on the CT2BIL score (D, p < 0.0001; E, p Z 0.019; F, p < 0.0001), in the Italian (A, D),
French (B, E) and UK (C, F), respectively. Log-rank tests. CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group
Performance Status.
Fig. 3. Decision curves to plot the net benefit achieved by making clinical decisions based on the performance status (PS) (blue) or on the final
multivariate model (red) for risk of death predictions at three months in the development cohort (A) and the external validation cohorts
(ItalyeB, FrencheC and UKeD). Net benefit Z true positive rate e (false positive rate  weighting factor). Weighting factor Z W Z
Threshold probability/(1-threshold probability)Z ratio of harm to benefit. The decision curve analysis shows a threshold of risk of death
at 3 months at which decisions will cause greater benefit for true positives and false positives will be reduced. Here, the decision is defined
by the possibility of not treating a patient with second-line chemotherapy (L2). In this context, the clinician must ensure that the patient is
at high risk of death at three months and minimise false positives, that is, patients who are still alive at three months who must be treated.
The grey curve represents the benefit achieved by making clinical decisions in all assuming that all patients would be dead at three months.
The black curve represents the benefit achieved by making clinical decisions in none assuming that all patients would be alive at three
months. Overall, the decision curve shows that the net benefit for decision based on our final multivariable model is of interest. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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Table 4
Summary of previously published retrospective studies of second-line chemotherapy in patients with advanced biliary tract carcinoma.
Author, Year (ref) Number of patients mPFS (months) mOS (months) Prognostic factors (multivariate analysis)
Brieau et al., 2015 [10] 196 3.2 6.7  PS 0-1
 PR/SD with L1
 CA19-9  400 UI/ml
Fornaro et al., 2014 [16] 300 3.2 7.2  PS 0
 CA19-9  152 UI/ml
 PFS with L1  6 months
 Surgery on primary tumour
Fornaro et al., 2015 [17] 174
Pooled analysis with
published data: 499
3.0
3.1
6.6
6.3
 PS 0
 CA19-9 < 157 UI/ml
 Locally advanced stage
Kim et al., 2017 [18] 321 1.9 6.5  Intra-hepatic CCA
 TTP with L1 > 4 months
 CA19-9 at diagnosis
 Metastatic stage at diagnosis
CA19-9: carbohydrate antigen 19-9, CCA: cholangiocarcinoma; L1: first-line chemotherapy, SD: stable disease, mPFS: median progression-free
survival, mOS: median overall survival, PFS: progression-free survival, PS: performance status, PR: partial response, TTP: time to tumour
progression.
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even in this large, well-documented, European database.
Better understanding of BTC prognosis may emerge
from molecular studies [21] and also from the develop-
ment of more informative databases including easily
available clinicobiological parameters that were not
available in our study, such as smoking status or
neutrophil-to-lymphocyte ratio [22,23].
Overall, our results highlight a considerable hetero-
geneity in survival in patients with aBTC receiving L2,
with median OS ranging from 3 to 13 months. A better
and adequate discrimination of these patient subgroups
is essential to improve therapeutic strategies at the pa-
tient level and reduce confusion in clinical research by
optimising the design of future clinical trials.Conflict of interest statement
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